* Surmodics Inc SRDX.OQ SRDX.O is expected to show a
rise in
quarterly revenue when it reports results on February 1 for the
period ending December 31 2023
* The Eden Prairie Minnesota-based company is expected to
report
a 18.9% increase in revenue to $29.644 million from $24.93
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.The company's guidance on November
8 2023, for the period ended December 31, was for revenue
between $29.50 million and $30.50 million.
* LSEG's mean analyst estimate for Surmodics Inc is for a
loss
of 30 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Surmodics
Inc is
$44.00, above its last closing price of $35.56.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 0.18 0.19 0.53 Beat 186.5
Jun. 30 2023 -0.22 0.05 0.52 Beat 893.7
Mar. 31 2023 -0.49 -0.51 -0.40 Beat 21.3
Dec. 31 2022 -0.65 -0.66 -0.50 Beat 23.8
Sep. -0.45 -0.45 -0.26 Beat 42.4
30 2022
Jun. 30 2022 -0.38 -0.38 -0.34 Beat 11.3
Mar. 31 2022 -0.35 -0.34 -0.22 Beat 35.3
Dec. 31 2021 -0.31 -0.31 -0.13 Beat 58.5
This summary was machine generated January 30 at 13:37 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)